{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RE-ACTIVE&page=5",
    "query": {
      "intervention": "RE-ACTIVE",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 296,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RE-ACTIVE&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RE-ACTIVE&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T15:46:35.567Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02229851",
      "title": "Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Disorder",
        "Adult Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "somapacitan",
          "type": "DRUG"
        },
        {
          "name": "somatropin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "23 Years to 79 Years"
      },
      "enrollment_count": 301,
      "start_date": "2014-10-31",
      "completion_date": "2018-05-07",
      "has_results": true,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229851"
    },
    {
      "nct_id": "NCT05528380",
      "title": "Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pregnancy",
        "Cannabis"
      ],
      "interventions": [
        {
          "name": "LPA + Fitbit Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Butler Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2022-01-30",
      "completion_date": "2024-10-15",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528380"
    },
    {
      "nct_id": "NCT03675477",
      "title": "A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "SHR0302",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reistone Biopharma Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 164,
      "start_date": "2019-04-13",
      "completion_date": "2021-02-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-02",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 3,
      "location_summary": "Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Lake Wales",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03675477"
    },
    {
      "nct_id": "NCT00488631",
      "title": "An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 50 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 100 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 200 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1228,
      "start_date": "2007-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-26",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 96,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Merced",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00488631"
    },
    {
      "nct_id": "NCT02349295",
      "title": "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab 80 mg Q4W",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab 80 mg Q2W",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2014-12-31",
      "completion_date": "2019-06-26",
      "has_results": true,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349295"
    },
    {
      "nct_id": "NCT01186328",
      "title": "EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia, Acute",
        "Lymphoblastic Leukemia, Acute, Childhood",
        "Leukemia, Lymphoblastic, Acute, T Cell",
        "Leukemia, Lymphoblastic, Acute"
      ],
      "interventions": [
        {
          "name": "EZN-3042",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "PEG-asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-08-24",
      "completion_date": "2012-01-10",
      "has_results": true,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186328"
    },
    {
      "nct_id": "NCT03100136",
      "title": "Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroinflammation"
      ],
      "interventions": [
        {
          "name": "[11C]PF-06809247",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2016-11-16",
      "completion_date": "2017-03-10",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03100136"
    },
    {
      "nct_id": "NCT02394028",
      "title": "A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Etrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1035,
      "start_date": "2015-03-20",
      "completion_date": "2021-09-07",
      "has_results": true,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 62,
      "location_summary": "Arcadia, California • La Jolla, California • Long Beach, California + 53 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Carlos",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02394028"
    },
    {
      "nct_id": "NCT03859713",
      "title": "Optimize Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Low Back Pain",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Physical Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mindfulness",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phase I Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phase II Switching",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 749,
      "start_date": "2019-03-22",
      "completion_date": "2024-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03859713"
    },
    {
      "nct_id": "NCT00657150",
      "title": "Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran etexilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2055,
      "start_date": "2008-03",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-07-02",
      "last_synced_at": "2026-10-19T15:46:35.567Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657150"
    }
  ]
}